29 Muharram 1447 - 24 July 2025
    
Sign-up for newsletter
Eye of Dubai
Business & Money | Monday 14 August, 2017 4:57 am |
Share:

Neopharma aims to establish footprint in other global markets after Japanese acquisition

Neopharma, one of UAE’s leading pharmaceutical manufacturing company is in the plans for major expansion, primarily in the Middle East and North African markets and parts of Asia. These plans take into account the impending growth of the industry in these markets. The increased push for compulsory health insurance schemes, increased demand of generics and hike in medical tourism numbers would provide a positive push.

“Being one of the largest pharmaceutical markets in the region, MENA’s lure can be attributed to its increasing population, drastically changing healthcare infrastructure and the government’s willingness to radically improve the healthcare systems in the country. Our aim for the region is help bridge the gap between the patented and the generic by providing products of high quality which aren’t a burden on the insurance companies,” stated Dr.B.R.Shetty, Chairman & Managing Director, Neopharma.

According to reports, Middle East and North Africa (MENA) region is forecasted to witness an increase in pharmaceutical expenditure to USD33.4bn by the end of 2017, up by nearly a billion american dollars from the previous year. The Saudi pharmaceutical market accounts for over 60% of the GCC and is  forecasted to grow at a rate of 9% up untill 2026 according to separate reports.

“The first phase of expansion would involve proliferation in the other Middle Eastern countries where Neopharma is aggressively pushing for licences and trade marks.  Neopharma’s focus on value-added drugs and not just generics is one of our key differentiators and we aim to add further value to the local health care industry. Furthermore, we have already invested over AED 100 million in setting up a state-of-the-art research and development facility,” added Dr.Shetty.

Apart from the GCC region, Neopharma has recently made significant investments in a state-of-the-art Japanese factory to the tune of AED 100 million. Additionally about AED 265 million have been spent in the acquisition of patents and licenses excluding an additional AED 515 million in the clinical studies. The Japanese facility will be manufacturing primarily nutraceuticals, one of which has been found effective for Type II diabetic patients and also those in the pre-diabetic stage.

NatuALA, the dietary supplement mentioned earlier is a breakthrough in the management of Type 2 diabetes. The UAE has been reported to have over one million people sufferin from diabetes out of which 450,000 are undiagnosed. The supplement under clinical studies being conducted across USA, Japan, UK and Bahrain; could very well provide to be a boon for diabetes patients.

Neopharma has commenced manufacturing NatuALA to address the needs of the ever increasing Type 2 diabetes patients in the GCC region and across the globe under license from SBI Pharma. SBI Neopharma will be distributing the product worldwide.

NatuALA reduces the blood glucose levels by insulin-independent method and keeps fasting glucose levels under critical levels. The dietary supplementary product with 60 patents prevalent in over 35 countries across the globe; utilizes a fermentation process to develop it. The process is easily scalable to suit its demands.

Share:
Print
Post Your Comment
ADD TO EYE OF Dubai
RELATED NEWS
MOST POPULAR